Dr. Dalia Rivenzon-Segal

Partner Patent Attorney Reinhold Cohn & Partners


  • Postdoctoral studies, the Weizmann Institute of Science. Investigating three-dimensional structure of proteins using cryo-Transmission Electron Microscopy (TEM).
  • Ph.D Chemistry, 2002, the Weizmann Institute of Science. Focusing on analysis of tumors’ physiology and metabolism using Magnetic Resonance Spectroscopy (MRS), Magnetic Resonance Imaging (MRI) and cell biology techniques.


Dr. Dalia Rivenzon-Segal is a partner and a patent attorney at the Reinhold Cohn Group’s Life Science and Chemistry practice.

Dalia is involved in drafting patent applications, prosecution, Freedom to Operate (FTO), and IP due diligence in medicinal chemistry, drug discovery and optimization, protein structure analysis, microscopy, molecular and cell biology.

Before joining the Reinhold Cohn Group, Dalia served as a senior scientist in the computational chemistry department of EPIX Pharmaceuticals, a drug discovery company, where she was involved in drug optimization projects and in-silico screening programs (ligand-based and structure-based).


Frohn M, Cee VJ, Lanman BA, Pickrell AJ, Golden J, Rivenzon-Segal D, Middleton S, Fiorino M, Xu H, Schrag M, Xu Y, McElvain M, Muller K, Siu J, Bürli R. Novel 5- and 6-subtituted benzothiazoles with improved physicochemical properties: potent S1P₁ agonists with in vivo lymphocyte-depleting activity. Bioorg Med Chem Lett. 22: 628-633, 2012

Cee VJ, Frohn M, Lanman BA, Golden J, Muller K, Neira S, Pickrell A, Arnett H, Buys J, Gore A, Fiorino M, Horner M, Itano A, Lee MR, McElvain M, Middleton S, Schrag M, Rivenzon-Segal D, Vargas HM, Xu H, Xu Y, Zhang X, Siu J, Wong M, Bürli RW. Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P1 and S1P5. ACS Med Chem Lett. 29: 107-112, 2010.

Lanman BA, Cee VJ, Cheruku SR, Frohn M, Golden J, Lin J, Lobera M, Marantz Y, Muller KM, Neira SC, Pickrell AJ, Rivenzon-Segal D, Schutz N, Sharadendu A, Yu X, Zhang Z, Buys J, Fiorino M, Gore A, Horner M, Itano A, McElvain M, Middleton S, Schrag M, Vargas HM, Xu H, Xu Y, Zhang X, Siu J, Bürli. RW. Discovery of a Potent, S1P3-Sparing Benzothiazole Agonist of Sphingosine-1-Phosphate Receptor 1 (S1P1). ACS Med Chem Lett. 9:102-106, 2010.

Sela I, Golan G, Strajbl M, Rivenzon-Segal D, Bar-Haim S, Bloch I, Inbal B, Shitrit A, Ben-Zeev E, Fichman M, Markus Y, Marantz Y, Senderowitz H, Kalid O. Curr Top Med Chem. 10: 638-656, 2010.

Rivenzon-Segal D, Wolf SG, Shimon L, Willison KR, Horovitz A. Sequential ATP induced allosteric transitions of the cytoplasmic chaperonin containing TCP-1 (CCT) revealed by Electron microscopy analysis. Nature Struct. Mol. Biol. 12:233-237,2005.

Danziger O,* Rivenzon-Segal D,* Wolf SG, Horovitz A. Conversion of the allosteric transition of GroEL from concerted to sequential by the single mutation Asp-155 -> Ala. Proc Natl Acad Sci U S A. 100:13797- 13802, 2003. (* equal contribution).

Rivenzon-Segal D, Boldin-Adamsky S, Seger D, Seger R, Degani. H. Glycolysis and glucose transporter 1 as markers of response to hormonal therapy in breast cancer. Int J Cancer. 107:177-182, 2003.

Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res. 621966-70, 2002.

Rivenzon-Segal D, Margalit R, Degani H. Glycolysis as a metabolic marker in orthotopic breast cancer, monitored by in vivo 13C MRS. Am J Physiol Endocrinol Metab. 283:E623-630, 2002.

Rivenzon-Segal D, Rushkin E, Polak-Charcon, S, Degani, H. Glucose transporters and transport kinetics in retinoic acid-differentiated T47D human breast cancer cells. Am. J. Physiol. 279: E508-E519, 2000.

Willner I, Riklin A, Shoham B, Rivenzon D, Katz E. Adv. Mater. 5., 912, 1993.


Ranking and Recognition


  • Association of Israel Patent Attorneys
Contact Us